A prospective study analysing Immune checkpoint blockade (ICB) response evaluation with MRI/MR elastography (MRE) in surgical and nonsurgical patients with HCC
Latest Information Update: 27 Feb 2020
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- 27 Feb 2020 New trial record
- 25 Jan 2020 Results assessing Immune checkpoint blockade (ICB) response evaluation with MRI/MR elastography (MRE) in surgical and nonsurgical patients with HCC, presented at the 2020 Gastrointestinal Cancers Symposium